Braftovi (encorafenib) plus Mektovi (binimetinib) is new BRAF-MEK inhibitor combination regimen approved by the Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

If you have a Hayes login, click here to view the full report on the Knowledge Center.